Opinion|Videos|October 18, 2024
The Role of Quality, Benchmarking and KPIs in ART Decision-Making
Author(s)Jeffrey Dunn, PharmD, MBA
Jeffrey Dunn, Pharm.D., MBA, discusses how quality measures, benchmarking and key performance indicators play a crucial role in their daily work by guiding decision-making, improving patient outcomes and ensuring the continuous enhancement of fertility treatment and assisted reproductive technology (ART) program effectiveness.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What is the role of quality, benchmarking and key performance indicators (KPIs) in your everyday
Advertisement
Related to this article
Christine Johnston warns a thin biosimilar pipeline keeps specialty costs high and slows innovation and urges payers to check their PBM’s top 25 drugs.
Speakers and researchers at this year's meeting in San Diego focused on drug pricing policy, getting savings to patients at the pharmacy counter and keeping people in charge of AI.
The generic twice-yearly HIV prevention shot is expected to cost $40 a year in 120 countries, 16 months after Gilead's original approval.
Annual healthcare costs jump by almost $25,000 with targeted therapy for atopic dermatitis that avoided costs from reduced hospitalizations and ER visits only partly offset, according to recently reported research findings.
Findings from an analysis of IQVIA claims data show a prevalence rate that is five times lower than previous reports. Some of the discrepancy could be chalked up to the difference between using claims data instead of self-reporting by survey respondents.
In the MDT-BRIDGE trial, 92% of patients with stage II-III lung cancer reached surgery or chemoradiation after a midtreatment tumor board review.
Epic Research finds over half of children with type 1 diabetes miss autoantibody testing, risking misdiagnosis and limiting early treatment options like Tzield.
Higher MRI-measured liver disease activity was linked to lower quality of life and more anxiety and activity problems in 802 adults with suspected MASLD/MASH in Europe.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Bronchiectasis 101: Why permanently dilated airways drive recurrent exacerbations
2
FDA tentatively approves first generic lenacapavir for HIV prevention in lower-income countries
3
From MFP fallout to AI guardrails: What stood out at AMCP Nexus 2026
4
Christine Johnston on the biosimilar pipeline and PBM formularies
5